Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774291 · ClinicalTrials.gov registry record · Early Phase 1
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
A Early Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02774291: Clinical Trial Early Phase 1 study, sponsored by Albert Einstein College of Medicine.
NCT02774291 is a Early Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02774291, a Early Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other places in the body (metastatic) and expresses the gene NY-ESO-1. Donor white blood cells that are treated in the laboratory with anti-cluster of differentiation (CD)3 may help treat metastatic cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Aldesleukin may stimulate white blood cells, including natural killer cells, to kill metastatic cancer cells. Giving anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes together with combination chemotherapy and aldesleukin may kill more cancer cells.
Primary Outcome
Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Filgrastim
- DRUG Fludarabine Phosphate
- BIOLOGICAL Aldesleukin
- BIOLOGICAL Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2020-08-04 |
| Phase | Early Phase 1 |
Why NCT02774291 stopped before completion
NCT02774291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02774291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02774291 about?
NCT02774291 is a clinical study titled "Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes". This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other...
What is the current status of trial NCT02774291?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-04-20. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT02774291?
The interventions under investigation include: Cyclophosphamide (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Aldesleukin (BIOLOGICAL), Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02774291?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02774291's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI